Studies genes behind immune reactions to blood transfusions in sickle cell disease
Compares genes in sickle cell disease patients with and without transfusion reactions.
Plain-language title generated from the registry record
Registry title: Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
Key facts
- Where
- Bethesda, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 99 years old?
Source: NCT06944067, who can take part
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Human Genome Research Institute (NHGRI)
- Trial code
- NCT06944067
- Record updated
- 11 September 2026
- Original description
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes of individuals that develop red blood cell alloimmunization after blood transfusions with those that do not develop alloimmunization. This may help us to create more targeted therapeutic interventions, which may improve the health of alloimmune responders.Read full original descriptionShow less
Observational Study to Determine Red Blood Cell Alloimmunization Risk Etiology in Patients With Sickle Cell Disease
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes of individuals that develop red blood cell alloimmunization after blood transfusions with those that do not develop alloimmunization. This may help us to create more targeted therapeutic interventions, which may improve the health of alloimmune responders.
Exclusion: Taking immunosuppressive medications at time of enrollment; History of transplant (e.g., organ, bone marrow, stem cell); An individual who meets any the following criteria will be excluded from participation in this study:; Impaired decision-making capability, with or without a legally authorized representative; Confirmed pregnancy.
INCLUSION CRITERIA; To be eligible to participate in this study, an individual must meet all of the following criteria:; Individual (> 2 years of age) with confirmed SCD diagnosis who meets at least one of the following conditions:; History of greater than ten administered transfusions or 20 transfusion units (where known); History of one or more antibody screens; Known candidate variant genotype.